← Back to headlines
Mesoblast Misses H1 Financial Estimates
Biotechnology company Mesoblast has reported its financial performance for the first half of the fiscal year, falling short of market estimates.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
